Gilead and GSK nab early ADCs
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
The month ahead: December’s upcoming events
Party season approaches; but first, conferences.
Next for Trodelvy: small-cell lung cancer
Second-line NSCLC is a $1.8bn write-off, and Gilead plans phase 3 in SCLC.
SITC 2024 – Arcus springs a TIGIT surprise
Reports of Arc-10's failure are greatly exaggerated, the company argues.
ASH 2024 preview – Arcellx disappoints
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
SITC 2024 preview – duelling TIGIT duds
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
The month ahead: November’s upcoming events
Conferences ramp up, and ASH abstracts near.
